Literature DB >> 18774354

Enhancement characteristics of benign and malignant focal peripheral nodules in the peripheral zone of the prostate gland studied using contrast-enhanced transrectal ultrasound.

J Tang1, J-C Yang, Y Luo, J Li, Y Li, H Shi.   

Abstract

AIM: To assess the value of contrast-enhanced grey-scale transrectal ultrasound (CETRUS) in predicting the nature of peripheral zone hypoechoic lesions of the prostate.
MATERIALS AND METHODS: Ninety-one patients with peripheral zone hypoechoic lesions on ultrasound were evaluated with CETRUS followed by lesion-specific and sextant transrectal ultrasound-guided biopsies. The enhancement patterns of the lesions were observed and graded subjectively using adjacent peripheral zone tissue as the reference. Time to enhancement (AT), time to peak intensity (TTP) and peak intensity (PI) were quantified within each nodule. Ultrasound findings were correlated with biopsy findings.
RESULTS: Transrectal ultrasound-guided biopsy of the hypoechoic lesions revealed prostate cancer in 44 patients and benign prostatic diseases in 47. The intensity of enhancement within the lesions were graded as no enhancement, increased, equal, or decreased compared with adjacent peripheral zone tissue in two, 30, five and seven in the prostate cancer group and 14, 15, four and 14 in the benign group, respectively. The difference was statistically significant (p<0.05). The peak enhancement intensity was found to be the most optimal discriminatory parameter (area under curve AUC 0.70; 95% CI: 0.58, 0.82).
CONCLUSION: Malignant hypoechoic nodules in the peripheral zone of the prostate are more likely to enhance early and more intensely on CETRUS. A non-enhanced hypoechoic peripheral zone lesion was more likely to be benign.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18774354     DOI: 10.1016/j.crad.2007.11.026

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  11 in total

1.  Contrast-enhanced ultrasound: The evolving applications.

Authors:  Hui-Xiong Xu
Journal:  World J Radiol       Date:  2009-12-31

Review 2.  The current status of contrast-enhanced ultrasound in China.

Authors:  Hui-Xiong Xu; Ming-De Lu
Journal:  J Med Ultrason (2001)       Date:  2010-04-21       Impact factor: 1.314

3.  Contrast-enhanced ultrasound imaging of active bleeding associated with hepatic and splenic trauma.

Authors:  F Lv; J Tang; Y Luo; Z Li; X Meng; Z Zhu; T Li
Journal:  Radiol Med       Date:  2011-04-19       Impact factor: 3.469

4.  Parameters of prostate cancer at contrast-enhanced ultrasound: correlation with prostate cancer risk.

Authors:  Guang Xu; Jian Wu; Ming-Hua Yao; Xu-Dong Yao; Bo Peng; Qing Wei; Hui-Xiong Xu; Rong Wu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

5.  Factors influencing the degree of enhancement of prostate cancer on contrast-enhanced transrectal ultrasonography: correlation with biopsy and radical prostatectomy specimens.

Authors:  J Jiang; Y-Q Chen; Y-K Zhu; X-H Yao; J Qi
Journal:  Br J Radiol       Date:  2012-06-14       Impact factor: 3.039

Review 6.  Update on prostate imaging.

Authors:  Jalil Afnan; Clare M Tempany
Journal:  Urol Clin North Am       Date:  2010-02       Impact factor: 2.241

7.  [New ultrasound technologies for the diagnostics of prostate cancer].

Authors:  T de Zordo; M Ladurner; W Horninger; S W Heijmink; W Jaschke; F Aigner; F Frauscher
Journal:  Radiologe       Date:  2011-11       Impact factor: 0.635

8.  Clinical application of contrast enhanced ultrasound to diagnose benign prostatic hyperplasia.

Authors:  Jingfang Shi; Xiaohua Yin; Rong Xu; Yingchun Wang; Lin Jin; Weiwei Gao
Journal:  Diagn Pathol       Date:  2014-07-01       Impact factor: 2.644

9.  Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer.

Authors:  Rogier R Wildeboer; Arnoud W Postema; Libertario Demi; Maarten P J Kuenen; Hessel Wijkstra; Massimo Mischi
Journal:  Eur Radiol       Date:  2016-12-21       Impact factor: 5.315

Review 10.  A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies.

Authors:  Koenraad van Renterghem; Gommert Van Koeveringe; Ruth Achten; Philip van Kerrebroeck
Journal:  Int Urol Nephrol       Date:  2009-06-03       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.